In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria
Genome-editing strategies, especially CRISPR-Cas9 systems, have substantially increased the efficiency of innovative therapeutic approaches for monogenic diseases such as primary hyperoxalurias (PHs). We have previously demonstrated that inhibition of glycolate oxidase using CRISPR-Cas9 systems repr...
Сохранить в:
| Главные авторы: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2022-06-01
|
| Серии: | Molecular Therapy: Methods & Clinical Development |
| Предметы: | |
| Online-ссылка: | http://www.sciencedirect.com/science/article/pii/S2329050122000365 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|